The present disclosure relates generally to alpha-helix mimetic structures and specifically to alpha-helix mimetic structures that are inhibitors of β-catenin. The disclosure also relates to applications in the treatment of viral and infectious diseases, including infection by HIV, HPV, HBV, HSV, and bacteria including